Patrícia Maciel Selected Research

Machado-Joseph Disease (Spinocerebellar Ataxia Type 3)

2/2022	Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D2 and Serotonin 1A and 2A Receptors in C. elegans.
1/2022	Novel Machado-Joseph disease-modifying genes and pathways identified by whole-exome sequencing.
11/2021	Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3.
1/2021	Neurotherapeutic effect of Hyptis spp. leaf extracts in Caenorhabditis elegans models of tauopathy and polyglutamine disease: Role of the glutathione redox cycle.
10/2019	From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
5/2019	Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
5/2019	Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease.
1/2018	Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3.
1/2018	Pharmacological Therapies for Machado-Joseph Disease.
11/2015	Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrícia Maciel Research Topics

Disease

24	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 02/2022 - 06/2009
15	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2022 - 06/2009
3	Disease Progression 11/2021 - 01/2018
3	Neuroinflammatory Diseases 07/2021 - 12/2018
2	Tauopathies 01/2021 - 12/2020
2	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 11/2020 - 06/2009
2	Mitochondrial Diseases (Mitochondrial Disease) 12/2018 - 01/2018
2	Tremor (Tremors) 12/2018 - 12/2014
2	Gliosis 01/2018 - 11/2015
2	Neurodevelopmental Disorders 02/2016 - 12/2013
2	Rett Syndrome (Rett's Disorder) 01/2008 - 06/2007
1	Inflammation (Inflammations) 05/2022
1	Mental Disorders (Mental Disorder) 02/2022
1	Psychotic Disorders (Schizoaffective Disorder) 02/2022
1	Ataxia (Dyssynergia) 11/2021
1	Frontotemporal Dementia (Semantic Dementia) 01/2021
1	Demyelinating Diseases (Demyelinating Disease) 10/2020
1	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 03/2020
1	Neoplasms (Cancer) 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Parkinsonian Disorders (Parkinsonism) 12/2018
1	Parkinson Disease (Parkinson's Disease) 12/2018
1	Movement Disorders (Movement Disorder) 01/2018
1	Epilepsy (Aura) 02/2016
1	Body Weight (Weight, Body) 11/2015
1	Proteostasis Deficiencies 06/2009
1	Migraine Disorders (Migraine) 01/2008
1	Intellectual Disability (Idiocy) 01/2008
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2008
1	Neuroferritinopathy 01/2006
1	Chorea (Rheumatic Chorea) 12/2005
1	Multiple Sclerosis 04/2004

Drug/Important Bio-Agent (IBA)

16	polyglutamineIBA 05/2022 - 06/2009
8	Ataxin-3IBA 02/2022 - 09/2009
8	Proteins (Proteins, Gene)FDA Link 02/2022 - 09/2009
4	Pharmaceutical PreparationsIBA 02/2022 - 05/2019
3	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 07/2021 - 12/2018
3	AntioxidantsIBA 01/2021 - 01/2019
3	EnzymesIBA 01/2021 - 04/2011
3	Citalopram FDA LinkGeneric 05/2019 - 11/2015
2	diazonaphthalenedisulfonic acid (NDS)IBA 01/2022 - 02/2016
2	Glutathione (Reduced Glutathione)IBA 01/2021 - 12/2020
2	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 05/2019 - 05/2019
2	ursodoxicoltaurineIBA 01/2019 - 12/2018
2	Neuroprotective AgentsIBA 01/2018 - 12/2014
2	Mitochondrial DNA (mtDNA)IBA 02/2015 - 01/2013
2	Apolipoproteins E (ApoE)IBA 12/2011 - 04/2004
2	UbiquitinIBA 04/2011 - 10/2010
1	Aripiprazole (Abilify)FDA Link 02/2022
1	Dopamine (Intropin)FDA LinkGeneric 02/2022
1	Antipsychotic Agents (Antipsychotics)IBA 02/2022
1	Choline (Choline Chloride)IBA 10/2020
1	N-acetylaspartate (N-acetyl aspartate)IBA 10/2020
1	Inositol (Myoinositol)IBA 10/2020
1	Phospholipids (Phosphatides)FDA LinkGeneric 10/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	PyridinesIBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 12/2018
1	CreatineIBA 01/2018
1	Mutant Proteins (Protein, Mutant)IBA 01/2018
1	CalbindinsIBA 01/2018
1	GuanineIBA 01/2017
1	Adenine FDA LinkGeneric 01/2017
1	CytosineIBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 06/2015
1	Valproic Acid (Depakote)FDA LinkGeneric 01/2015
1	Beclin-1IBA 12/2014
1	Lithium ChlorideIBA 12/2014
1	LithiumIBA 12/2014
1	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 04/2014
1	ApolipoproteinsIBA 12/2011
1	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2011
1	Messenger RNA (mRNA)IBA 05/2010
1	DNA (Deoxyribonucleic Acid)IBA 05/2010
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2008
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 01/2008
1	NucleotidesIBA 01/2008
1	3' Untranslated Regions (3' UTR)IBA 01/2008
1	Methyl-CpG-Binding Protein 2IBA 06/2007
1	tributyl phosphate (TBP)IBA 01/2006
1	Nonsense Codon (Nonsense Mutation)IBA 12/2005

Therapy/Procedure

6	Therapeutics 11/2021 - 12/2013
1	Transplantation 11/2021